Evidence map›Paper›PMID 35445305›Full record

ArticleCancer immunology, immunotherapy : CII2022

Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.

Takashi Yoshida, Chisato Ohe, Katsuhiro Ito, Hideaki Takada, Ryoichi Saito, Yuki Kita, Takeshi Sano, Koji Tsuta, Hidefumi Kinoshita, Hiroshi Kitamura and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Takashi YoshidaDepartment of Urology and Andrology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan. yoshidtk@takii.kmu.ac.jp.
Chisato OheCorporate Sponsored Research Programs for Multicellular Interactions in Cancer, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan.
Katsuhiro ItoDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan.
Hideaki TakadaDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan.
Ryoichi SaitoDepartment of Urology and Andrology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan.
Yuki KitaDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan.
Takeshi SanoDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan.
Koji TsutaCorporate Sponsored Research Programs for Multicellular Interactions in Cancer, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan.
Hidefumi KinoshitaDepartment of Urology and Andrology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata City, Osaka, 573-1010, Japan.
Hiroshi KitamuraDepartment of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Takashi KobayashiDepartment of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyoku, Kyoto, 606-8507, Japan. selecao@kuhp.kyoto-u.ac.jp.
Japan Urological Oncology Group
Kansai Medical University · JPKyoto University · JPUniversity of Toyama · JPUniversity of Tsukuba · JP

Funding

Japan Society for the Promotion of Science KAKENHI fund 20K07601the Japan Society for the Promotion of Science KAKENHI fund # 25713055
6 · The paper itself

Abstract

Despite recent advancements in immunotherapy, urothelial carcinoma patients with liver metastasis have a poor response to immune checkpoint inhibitors (ICIs) and short survival durations. Here, we investigated the clinical activity and molecular correlates of resistance to ICI in patients with metastatic urothelial carcinoma (mUC), focusing on liver metastasis. In this study, 755 patients with mUC who received pembrolizumab (JUOG cohort), 144 mUC patients who were treated with atezolizumab (IMvigor210 cohort), and 59 mUC patients who had metastatic samples available were enrolled. The presence of liver metastasis was associated with increased peripheral monocytes and a reduction in lymphocytes when compared with other metastatic sites, and a poor prognosis for ICI therapy. The peripheral monocyte-to-lymphocyte ratio was significantly correlated with the CD163

Indexed as

Carcinoma, Transitional CellLiver NeoplasmsUrinary Bladder NeoplasmsBiomarkers, TumorHumansImmune Checkpoint InhibitorsImmunologic FactorsTransforming Growth Factor betaBiomarkers, TumorImmune Checkpoint InhibitorsImmunologic FactorsTransforming Growth Factor betaImmune checkpoint inhibitorImmunohistochemistryLiver metastasisPrognostic classificationRNA-seqUrothelial carcinoma

Identifiers

PMID35445305
PMCPMC10992465
OpenAlexW4224232605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.